Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,630   -0,006   (-0,94%) Dagrange 0,626 - 0,645 149.116   Gem. (3M) 1,2M

Novacyt de volgende biotech raket!

Volgen
70.761 Posts
Pagina: «« 1 ... 3502 3503 3504 3505 3506 ... 3539 »» | Laatste | Omlaag ↓
  2. forum rang 10 voda 13 september 2023 15:36
    Novacyt S.A.

    (“Novacyt”, the “Company” or the “Group”)
    Notice of Half Year 2023 Results and Investor Presentation

    Paris, France and Eastleigh, UK – 13 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
    international specialist in clinical diagnostics, announces that it will report its unaudited financial results for the six
    months ended 30 June 2023 on Thursday, 28 September 2023.

    Investor webinar

    An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance
    Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place
    at 12.30pm BST on Thursday, 28 September 2023.

    The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A
    session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor
    Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.
    Automated French subtitling will be available throughout the presentation.
    Investors can sign up for the webinar via:

    www.investormeetcompany.com/novacyt-s...
    Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

    novacyt.com/notice-of-half-year-2023-...
  5. forum rang 10 voda 14 september 2023 08:26
    Novacyt S.A.

    (“Novacyt”, the “Company” or the “Group”)

    AGM voting

    Paris, France, and Eastleigh UK – 14 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
    international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company’s
    rescheduled Annual General Meeting (“AGM”), which will be held at 1pm BST/2pm CEST on 5 October 2023 as an
    open virtual meeting.

    The Company’s Annual General Meeting (“AGM”) will be held exclusively as an open online meeting at 1pm
    BST/2pm CEST on Thursday, 5 October 2023. As this is a rescheduled meeting, all previous votes are now void and
    all shareholders must resubmit their votes.

    As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary
    resolutions. All materials can be found at www.novacyt.com/investors.
    Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the
    Notice of the AGM.

    Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at
    least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting
    rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions
    set out below.

    Shareholders can vote in advance of the AGM by:
    • Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it
    and returning it together with evidence of their shareholding which must be in the form of a share
    certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex
    09, or via email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later
    than 2 October 2023 inclusive.
    • Voting on-line using the Votaccess portal www.actionnaire.cic-marketsolutions.eu if securities held
    on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis,
    Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank,
    Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 15 September 2023
    to 4 October 2023 2pm BST/3pm CEST.
    • Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such
    as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

    Shareholders can register for the AGM and access the online meeting by visiting
    novacytagm23.eventcaster.co.uk. Registration must be accompanied by formal evidence of shareholding.
    As this is a rescheduled meeting, all previous registrations are now void and all shareholders must re-register.
    Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the
    meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

    Shareholders who have voted (through a proxy, via their broker, nominee, bank, authorised intermediary,
    Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM online but will not be able to vote
    twice.

    Following the meeting, a recording of the AGM will be available on the Company’s website at
    www.novacyt.com/investors.

    novacyt.com/agm-voting-4/
  9. forum rang 10 voda 15 september 2023 17:13
    Kabinet rekent op 4 miljoen herhaalvaccinaties tegen corona: 300.000 prikken per week in GGD-hallen

    Komend najaar komt er weer een grote coronavaccinatiecampagne. Vanaf oktober tot het einde van het jaar kunnen alle 60-plussers, de griepprikgroep, zwangeren, mensen met afweerstoornissen en zorgmedewerkers een herhaalprik krijgen. Dat gebeurt voornamelijk in GGD-locaties.

    Niels Klaassen 13-09-23, 13:26 Laatste update: 13-09-23, 15:25
    Dat meldt minister van Volksgezondheid Ernst Kuipers (D66) in een brief aan de Tweede Kamer. Het coronavirus veroorzaakt allang geen crisissituatie meer, maar mensen in risicogroepen en ouderen kunnen nog altijd flink ziek worden door een besmetting. Zij krijgen vanaf oktober de gelegenheid een herhaalprik te halen tegen het virus, de vaccinaties zijn aangepast op omikronvariant XBB 1.5.

    Voor meer, zie link:

    www.ad.nl/politiek/kabinet-rekent-op-...
  10. forum rang 10 voda 15 september 2023 17:48
    Slotkoers 31 dec. 2022 1,2295

    Slotkoers 06 jan. 2023 1,0355 -0,194 = -15.78% Enorm volatiele week.
    Slotkoers 13 jan. 2023 0,943 -0,0925 = -8.93%
    Slotkoers 20 jan. 2023 0,8866 -0,0564 = -5.98%
    Slotkoers 27 jan. 2023 0,853 -0,0336 = -3.79%
    Slotkoers 03 feb. 2023 0,7768 -0,0762 = -8.93%
    Slotkoers 10 feb. 2023 0,7534 -0,0234 = -3.01%
    Slotkoers 17 feb. 2023 0,72 -0,0334 = -4.43%
    Slotkoers 24 feb. 2023 0,7362 +0,0162 = +2.25% De eerste week met een PLUSJE
    Slotkoers 03 mrt. 2023 0,6938 -0,0424 = -5.76%
    Slotkoers 10 mrt. 2023 0,66 -0,0338 = -4.87%
    Slotkoers 17 mrt. 2023 0,6206 -0,0394 = -5.97%
    Slotkoers 24 mrt. 2023 0,612 -0,0086 = -1.39%
    Slotkoers 31 mrt. 2023 0,64 +0,028 = +4.58%
    Slotkoers 06 apr. 2023 0,625 -0,015 = -2.34%
    Slotkoers 14 apr. 2023 0,6335 +0,085 = +1.36%
    Slotkoers 21 apr. 2023 0,591 -0,0425 = -6.71%
    Slotkoers 28 apr. 2023 0,5625 -0,0285 = -4.82% PB Finale eindcijfers 2022
    Slotkoers 05 mei 2023 0,5175 -0,045 = -8.00%
    Slotkoers 12 mei 2023 0,499 -0,0185 = -3.57%
    Slotkoers 19 mei 2023 0,479 -0,02 = -4.01%
    Slotkoers 26 mei 2023 0,4662 -0,0128 = -2.67%
    Slotkoers 02 jun. 2023 0,481 +0,0148 = +3.17% Eindelijk een ommekeer?
    Slotkoers 09 jun. 2023 0,496 +0,015 = +3.12%
    Slotkoers 16 jun. 2023 0,4612 -0,0348 = -7.02%
    Slotkoers 23 jun. 2023 0,4406 -0,0206 = -4.47%
    Slotkoers 30 jun. 2023 0,4238 -0,0168 = -3.81%
    Slotkoers 07 jul. 2023 0,4788 +0,055 = +12.98% PB Overname Yourgene (Top was 0,59 ruim 40%)
    Slotkoers 14 jul. 2023 0,515 +0,0362 = +7.56%
    Slotkoers 21 jul. 2023 0,54 +0,025 = +4.85%
    Slotkoers 28 jul. 2023 0,716 +0,176 = +32.59% PB Trading update 1 st halfyear.
    Slotkoers 04 aug. 2023 0,725 +0,009 = +1.26%
    Slotkoers 11 aug. 2023 0,888 +0,163 = +22.48%
    Slotkoers 18 aug. 2023 0,931 +0,043 = +4.84% PB Overname Yourgene akkoord.
    Slotkoers 25 aug. 2023 0,866 -0,065 = -6.98%
    Slotkoers 01 sep. 2023 0,86 -0,006 = -0.69%
    Slotkoers 08 sep. 2023 0,931 +0,071 = +8.26% PB Yourgene
    Slotkoers 15 sep. 2023 0,8325 - 0,0985 = -10.58%

    Jaarrendement t.o.v. van 31 december 2022 -0,397 = -32.29%

    Maandrendementen: (t.o.v. slot vorige maand)

    Slotkoers 31 jan. 2023 0,8084 -0,4211 = -34.25%
    Slotkoers 28 feb. 2023 0,709 -0,0994 = -12.30%
    Slotkoers 31 mrt. 2023 0,64 -0,069 = -9.73%
    Slotkoers 28 apr. 2023 0,5625 -0,0775 = -12.11%
    Slotkoers 31 mei 2023 0,466 -0,0965 = -17.16%
    Slotkoers 30 jun. 2023 0,4238 -0,0422 = -9.06%
    Slotkoers 31 jul. 2023 0,7295 +0.3057 = +72.13!!%
    Slotkoers 31 aug. 2023 0,885 +0,1555 = +21.32%
    Slotkoers 15 sep. 2023 0,8325 -0,0525 = -5.93%
  14. forum rang 10 voda 22 september 2023 17:53
    Slotkoers 31 dec. 2022 1,2295

    Slotkoers 06 jan. 2023 1,0355 -0,194 = -15.78% Enorm volatiele week.
    Slotkoers 13 jan. 2023 0,943 -0,0925 = -8.93%
    Slotkoers 20 jan. 2023 0,8866 -0,0564 = -5.98%
    Slotkoers 27 jan. 2023 0,853 -0,0336 = -3.79%
    Slotkoers 03 feb. 2023 0,7768 -0,0762 = -8.93%
    Slotkoers 10 feb. 2023 0,7534 -0,0234 = -3.01%
    Slotkoers 17 feb. 2023 0,72 -0,0334 = -4.43%
    Slotkoers 24 feb. 2023 0,7362 +0,0162 = +2.25% De eerste week met een PLUSJE
    Slotkoers 03 mrt. 2023 0,6938 -0,0424 = -5.76%
    Slotkoers 10 mrt. 2023 0,66 -0,0338 = -4.87%
    Slotkoers 17 mrt. 2023 0,6206 -0,0394 = -5.97%
    Slotkoers 24 mrt. 2023 0,612 -0,0086 = -1.39%
    Slotkoers 31 mrt. 2023 0,64 +0,028 = +4.58%
    Slotkoers 06 apr. 2023 0,625 -0,015 = -2.34%
    Slotkoers 14 apr. 2023 0,6335 +0,085 = +1.36%
    Slotkoers 21 apr. 2023 0,591 -0,0425 = -6.71%
    Slotkoers 28 apr. 2023 0,5625 -0,0285 = -4.82% PB Finale eindcijfers 2022
    Slotkoers 05 mei 2023 0,5175 -0,045 = -8.00%
    Slotkoers 12 mei 2023 0,499 -0,0185 = -3.57%
    Slotkoers 19 mei 2023 0,479 -0,02 = -4.01%
    Slotkoers 26 mei 2023 0,4662 -0,0128 = -2.67%
    Slotkoers 02 jun. 2023 0,481 +0,0148 = +3.17% Eindelijk een ommekeer?
    Slotkoers 09 jun. 2023 0,496 +0,015 = +3.12%
    Slotkoers 16 jun. 2023 0,4612 -0,0348 = -7.02%
    Slotkoers 23 jun. 2023 0,4406 -0,0206 = -4.47%
    Slotkoers 30 jun. 2023 0,4238 -0,0168 = -3.81%
    Slotkoers 07 jul. 2023 0,4788 +0,055 = +12.98% PB Overname Yourgene (Top was 0,59 ruim 40%)
    Slotkoers 14 jul. 2023 0,515 +0,0362 = +7.56%
    Slotkoers 21 jul. 2023 0,54 +0,025 = +4.85%
    Slotkoers 28 jul. 2023 0,716 +0,176 = +32.59% PB Trading update 1 st halfyear.
    Slotkoers 04 aug. 2023 0,725 +0,009 = +1.26%
    Slotkoers 11 aug. 2023 0,888 +0,163 = +22.48%
    Slotkoers 18 aug. 2023 0,931 +0,043 = +4.84% PB Overname Yourgene akkoord.
    Slotkoers 25 aug. 2023 0,866 -0,065 = -6.98%
    Slotkoers 01 sep. 2023 0,86 -0,006 = -0.69%
    Slotkoers 08 sep. 2023 0,931 +0,071 = +8.26% PB Yourgene
    Slotkoers 15 sep. 2023 0,8325 - 0,0985 = -10.58%
    Slotkoers 22 sep. 2023 0,78 - 0,0525 = -6.31%

    Jaarrendement t.o.v. van 31 december 2022 -0,4495 = -36.56%

    Maandrendementen: (t.o.v. slot vorige maand)

    Slotkoers 31 jan. 2023 0,8084 -0,4211 = -34.25%
    Slotkoers 28 feb. 2023 0,709 -0,0994 = -12.30%
    Slotkoers 31 mrt. 2023 0,64 -0,069 = -9.73%
    Slotkoers 28 apr. 2023 0,5625 -0,0775 = -12.11%
    Slotkoers 31 mei 2023 0,466 -0,0965 = -17.16%
    Slotkoers 30 jun. 2023 0,4238 -0,0422 = -9.06%
    Slotkoers 31 jul. 2023 0,7295 +0.3057 = +72.13!!%
    Slotkoers 31 aug. 2023 0,885 +0,1555 = +21.32%
    Slotkoers 22 sep. 2023 0,78 -0,105 = -11.86%
  15. forum rang 10 voda 28 september 2023 08:08
    Please find the attached RNS issued this morning.

    An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place at 12.30pm BST today.

    The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Automated French subtitling will be available throughout the presentation.

    Investors can sign up for the webinar via:

    www.investormeetcompany.com/novacyt-s...

    Kind regards,

    Mandy Cowling

    Corporate and Investor Relations Manager

    mandy.cowling@novacyt.com

    Novacyt Group

    www.novacyt.com

    LinkedIn

    Mobile: +44 (0) 7785 541 259

    York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG?
  17. forum rang 10 voda 28 september 2023 08:16
    Ach ja, wordt dit ooit nog opgelost?

    Trade and other receivables has fallen by £0.4m to £33.3m at 30 June 2023 in line with a decline in sales. The trade receivables balance includes a £24.0m unpaid DHSC invoice raised in December 2020, in respect of products delivered during 2020 that remains unpaid at the date of publishing the accounts. Recovery of the invoice is dependent on the outcome of the contract dispute. Also included in trade and other receivables is a £8.2m VAT receivable balance (December 2022: £8.3m), that mainly relates to UK VAT paid on sales invoices in dispute with the DHSC. As these sales have not been recognised in accordance with IFRS 15, the revenue, trade receivable and VAT element of the transactions have been reversed, resulting in a VAT debtor balance.
  18. forum rang 10 DeZwarteRidder 28 september 2023 08:19
    Novacyt S.A.
    (“Novacyt”, the “Company” or the “Group”)
    2023 Interim Results
    Company positioned for long-term sustainable growth following the acquisition of Yourgene Health
    Paris, France and Eastleigh, UK – 28 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
    international specialist in clinical diagnostics, announces its unaudited interim results for the six months ended 30
    June 2023.
    Operational highlights (including post-period end)
    • Completed the strategic acquisition of Yourgene Health plc (“Yourgene”), significantly enhancing Novacyt’s
    global diagnostics business, adding scale and diversification to accelerate long-term growth.
    • Successfully developed nine multiplex RUO (research use only) assays in key infectious disease areas.
    • IVD certification process: initiated verification and validation activities for two of the Company’s developed
    multiplex products, with the aim of certifying them as in vitro diagnostics (IVD) under the UKCA mark,
    expected to complete during Q4 2023.
    • Instrument sales recovery: Following the market saturation during the COVID-19 pandemic, the Group’s
    instrument sales are returning to normal levels with Q2 2023 sales up by 66% vs Q1 2023.
    • Recently launched Co-prep™ extraction system for research use and CE marked both q16 and q32
    instruments.
    • On track to complete IVDR clinical trial for winter respiratory panel, genesig™ Real-time PCR SARS-CoV-2
    Winterplex, in early 2024.
    • Exclusive development agreement with Eluceda Ltd to develop novel biosensor technology in the fields of
    human and animal in vitro diagnostics, life science research and animal speciation.

    Financial highlights
    • Group revenue for H1 2023 of £3.3m of which £0.5m relates to COVID-19 (H1 2022: £16.5m of which
    £13.0m was related to COVID-19).
    o Revenue for the non-COVID-19 portfolio totalled £2.8m representing 85% of total revenue (H1
    2022: £3.5m). As previously signalled, H1 2022 is a high comparator particularly in instrumentation,
    where sales were linked to COVID-19.
    o Non-COVID-19 revenue continues to build with Q2 2023 showing 3% growth over Q1 2023 and 10%
    growth vs Q4 2022.
    • Group gross margin increased to 50% (£1.7m) in H1 2023 (H1 2022: 24% (£4.0m)), due to lower stock write
    offs, but is still impacted by further stock provisions as a result of lower than anticipated COVID-19 sales.
    • Group operating costs fell by £4.1m to £7.0m in H1 2023 compared with £11.1m in H1 2022.
    • Group EBITDA loss before exceptionals reduced to £5.4m in H1 2023 (H1 2022: £7.1m loss).
    • Loss after tax reduced to £8.3m in H1 2023 (H1 2022: £8.7m).
    • Cash position at 30 June 2023 was £81.7m (FY 2022: £87.0m) and the Company remains debt free.
    • Acquired the entire share capital of Yourgene on 8 September 2023 for £16.7m, settled in cash.
70.761 Posts
Pagina: «« 1 ... 3502 3503 3504 3505 3506 ... 3539 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee